The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Summary of CLL trials presented at ASH 2016
Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany summarizes key trials on chronic lymphocytic leukemia (CLL) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Stilgenbauer explains that positive trials after chemoimmunotherapy with maintenance treatment (lenalidomide), in the frontline and the relapsed/refractory setting were presented. He also outlines the long-term follow-ups of single agent trials on ibrutinib, venetoclax and idelalisib and discusses new developments with agents that have not been licensed to date, such as zanubrutinib (BGB-3111) and acalabrutinib.
